918642-72-5

Basic information

• Product Name: 1-((4-fluorophenyl)(methyl)carbamoyl)cyclopropane-1-carboxylic acid
• Synonyms: 1-((4-fluorophenyl)(methyl)carbamoyl)cyclopropane-1-carboxylic acid
• CAS NO: 918642-72-5
• Molecular Weight: 237.231
• Mol File: 918642-72-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-((4-fluorophenyl)(methyl)carbamoyl)cyclopropane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-((4-fluorophenyl)(methyl)carbamoyl)cyclopropane-1-carboxylic acid(918642-72-5)
• EPA Substance Registry System: 1-((4-fluorophenyl)(methyl)carbamoyl)cyclopropane-1-carboxylic acid(918642-72-5)

Safety Data

• Hazardous Substances Data: 918642-72-5(Hazardous Substances Data)

Upstream product

• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 459-59-6 4-fluoro-N-methylaniline 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS

Disclosed herein are compounds of Formula (I) which inhibit, regulate and/or modulate tyrosine kinase receptors, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities, compositions containing the compounds, methods of using the compounds to treat kinase-dependent diseases and conditions, and methods for making the compounds.

CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.